MCID: THY125
MIFTS: 50

Thyroid Gland Medullary Carcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Thyroid Gland Medullary Carcinoma

MalaCards integrated aliases for Thyroid Gland Medullary Carcinoma:

Name: Thyroid Gland Medullary Carcinoma 12 15
Medullary Thyroid Carcinoma 12 15
Medullary Carcinoma of the Thyroid Gland 12
Ultimobranchial Thyroid Tumour 12
Ultimobranchial Thyroid Tumor 12
Thyroid Cancer, Medullary 43

Classifications:



External Ids:

Disease Ontology 12 DOID:3973
MeSH 43 C536914
NCIt 49 C3879
SNOMED-CT 67 255032005
UMLS 71 C0238462

Summaries for Thyroid Gland Medullary Carcinoma

Disease Ontology : 12 A thyroid gland carcinoma that has material basis in parafollicular cells.

MalaCards based summary : Thyroid Gland Medullary Carcinoma, also known as medullary thyroid carcinoma, is related to multiple endocrine neoplasia, type iia and multiple endocrine neoplasia. An important gene associated with Thyroid Gland Medullary Carcinoma is RET (Ret Proto-Oncogene), and among its related pathways/superpathways are Peptide ligand-binding receptors and MicroRNAs in cancer. The drugs Tyrosine and Glucagon have been mentioned in the context of this disorder. Affiliated tissues include thyroid, testes and lymph node.

Related Diseases for Thyroid Gland Medullary Carcinoma

Diseases related to Thyroid Gland Medullary Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 377)
# Related Disease Score Top Affiliating Genes
1 multiple endocrine neoplasia, type iia 34.2 RET NTRK1 MEN1 CALCA
2 multiple endocrine neoplasia 33.9 RET MEN1 CALCA
3 multiple endocrine neoplasia, type iib 33.6 RET NTRK1 MEN1 CALCA
4 goiter 31.7 TG SST RET CALCA
5 thyroiditis 31.6 TG RET CALCA
6 rare tumor 31.6 SST RET
7 nodular goiter 31.5 TG RET CALCA
8 thyroid carcinoma, familial medullary 31.5 TG SSTR5 SSTR2 SSTR1 SST RET
9 primary hyperparathyroidism 31.3 RET MEN1 CHGA CALCA
10 differentiated thyroid carcinoma 31.3 TG RET NTRK1
11 parathyroid adenoma 31.2 RET MEN1 CHGA CALCA
12 multinodular goiter 31.2 TG RET MIR138-1 CALCA
13 papillary carcinoma 31.1 TG RET NTRK1 CHGA CALCA
14 neuroendocrine tumor 31.1 SSTR2 SST RET MEN1 CHGA CCKBR
15 hirschsprung disease 1 31.0 RET NTRK1 MIR31 CALCA
16 neuroendocrine carcinoma 31.0 SST MEN1 CHGA CEACAM5 CALCA
17 multiple mucosal neuroma 30.9 RET NTRK1 CALCA
18 malignant pheochromocytoma 30.9 SST CHGA CALCA
19 paraganglioma 30.9 TG SST RET MEN1 CHGA CALCA
20 conn's syndrome 30.9 SST MEN1 CHGA CALCA
21 adenoma 30.9 TG SSTR5 SSTR2 SST RET MEN1
22 carcinoid tumors, intestinal 30.8 SSTR2 SST MEN1 CHGA
23 pituitary tumors 30.8 SSTR5 SST MEN1
24 carney complex variant 30.8 SST RET MEN1
25 fetal adenoma 30.7 TG CALCA
26 extra-adrenal pheochromocytoma 30.7 RET CHGA
27 endocrine gland cancer 30.7 SST RET MIR9-1 MIR31 MIR222 MIR183
28 thyroid carcinoma 30.6 TG RET NTRK1 CALCA
29 multiple endocrine neoplasia, type i 30.6 SST RET MEN1 CHGA
30 intestinal obstruction 30.6 SST RET CEACAM5
31 parathyroid carcinoma 30.6 RET MEN1 CALCA
32 hyperparathyroidism 30.6 RET MEN1 CHGA CALCA
33 hyperthyroidism 30.5 TG SST CALCA
34 thyroid lymphoma 30.5 TG CALCA
35 duodenal somatostatinoma 30.5 SST MEN1
36 neurofibromatosis, type i 30.5 SST RET MEN1
37 endemic goiter 30.5 TG CALCA
38 megacolon 30.5 RET NTRK1 MIR31
39 small cell cancer of the lung 30.4 SSTR2 SST CHGA CEACAM5 CALCA
40 mucoepidermoid carcinoma 30.4 TG CHGA CEACAM5 CALCA
41 constipation 30.4 SST RET CHGA CALCA
42 follicular adenoma 30.4 TG RET NTRK1 MEN1 CALCA
43 von hippel-lindau syndrome 30.4 RET MEN1 CHGA
44 neuroblastoma 30.4 SSTR2 SST RET NTRK1 MEN1 CHGA
45 thyroid gland disease 30.4 TG SST RET MIR9-1 MIR222 MIR183
46 ganglioneuroma 30.3 SST RET NTRK1 CHGA
47 adrenal carcinoma 30.3 SST MEN1 CHGA
48 thyroid gland follicular carcinoma 30.3 TG RET NTRK1 MIR222 MIR183 CALCA
49 parathyroid gland disease 30.2 TG RET MIR31 MEN1 CALCA
50 thyroid gland anaplastic carcinoma 30.2 TG RET NTRK1 MIR222 MIR183 MIR138-1

Graphical network of the top 20 diseases related to Thyroid Gland Medullary Carcinoma:



Diseases related to Thyroid Gland Medullary Carcinoma

Symptoms & Phenotypes for Thyroid Gland Medullary Carcinoma

Drugs & Therapeutics for Thyroid Gland Medullary Carcinoma

Drugs for Thyroid Gland Medullary Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 107)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tyrosine Approved, Investigational, Nutraceutical Phase 4 60-18-4 6057
2
Glucagon Approved Phase 3 16941-32-5
3
Liraglutide Approved Phase 3 204656-20-2 44147092
4 Hormone Antagonists Phase 3
5 Hormones Phase 3
6 Glucagon-Like Peptide 1 Phase 3
7 Insulin, Globin Zinc Phase 3
8 Hypoglycemic Agents Phase 3
9 Incretins Phase 3
10 insulin Phase 3
11
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
12
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
13
Histamine Approved, Investigational Phase 1, Phase 2 51-45-6 774
14
Doxorubicin Approved, Investigational Phase 1, Phase 2 23214-92-8 31703
15
Lenograstim Approved, Investigational Phase 1, Phase 2 135968-09-1
16
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
17
Sodium citrate Approved, Investigational Phase 2 68-04-2
18
Tamoxifen Approved Phase 2 10540-29-1 2733526
19
Melphalan Approved Phase 2 148-82-3 460612 4053
20
Pancrelipase Approved, Investigational Phase 2 53608-75-6
21
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
22
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
23
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
24
Pasireotide Approved Phase 2 396091-73-9 9941444
25
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
26
Iodine Approved, Investigational Phase 2 7553-56-2 807
27
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
28
Nintedanib Approved Phase 2 656247-17-5 56843413
29
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
30
Salmon calcitonin Approved, Investigational Phase 2 47931-85-1 16129616
31
Dacarbazine Approved, Investigational Phase 1, Phase 2 4342-03-4 5351166
32
Capecitabine Approved, Investigational Phase 1, Phase 2 154361-50-9 60953
33
Bortezomib Approved, Investigational Phase 1, Phase 2 179324-69-7 387447 93860
34
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
35
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441
36
Levodopa Approved Phase 2 59-92-7 6047
37
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
38
Glycine Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 56-40-6 750
39
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
40
Imetelstat Investigational Phase 2 868169-64-6
41 Molgramostim Investigational Phase 2 99283-10-0
42
Calcitonin gene-related peptide Investigational Phase 2 83652-28-2
43 Pancreatic Polypeptide Investigational Phase 2 59763-91-6
44 Immunosuppressive Agents Phase 2
45 Immunologic Factors Phase 2
46 Anti-Infective Agents Phase 2
47 Anti-Bacterial Agents Phase 2
48 Antibodies, Bispecific Phase 2
49
Histamine Phosphate Phase 1, Phase 2 51-74-1 65513
50 Antibodies, Monoclonal Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 63)
# Name Status NCT ID Phase Drugs
1 The Use of Lu177 in the Treatment of Progressive and Unresectable Metastatic Medullary Thyroid Cancer Unknown status NCT01915485 Phase 4
2 A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients Recruiting NCT01896479 Phase 4 Cabozantinib (XL184) 140 mg;Cabozantinib (XL184) 60 mg;Placebo tablet;Placebo capsule
3 An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease Active, not recruiting NCT01496313 Phase 4 300mg vandetanib;150mg vandetanib
4 A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Medullary Thyroid Carcinoma(ALTER01031) Completed NCT02586350 Phase 2, Phase 3 Anlotinib;Placebo
5 Liraglutide in the Treatment of Type 1 Diabetes Mellitus Completed NCT01722266 Phase 3 Liraglutide;Placebo
6 A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531) Recruiting NCT04211337 Phase 3 Selpercatinib;Cabozantinib;Vandetanib
7 An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer Active, not recruiting NCT00410761 Phase 3 ZD6474 (Vandetanib)
8 A Phase II Study to Investigate the Efficacy of RAD001 (Afinitor®, Everolimus) in Patients With Irresectable Recurrent or Metastatic Differentiated, Undifferentiated (Anaplastic) and Medullary Thyroid Carcinoma Unknown status NCT01118065 Phase 2 everolimus
9 Phase II Trial of Thalidomide for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas and Medullary Thyroid Carcinomas Completed NCT00026533 Phase 2 thalidomide
10 A Phase I/II, Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300 mg/Day in Japanese Patients With Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma Completed NCT01661179 Phase 1, Phase 2 Vandetanib 300mg
11 A Multi-center, Single-arm, Open-label Phase II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Sorafenib in Japanese Patients With Anaplastic Thyroid Carcinoma or Locally Advanced or Metastatic Medullary Thyroid Carcinoma Completed NCT02114658 Phase 2 Sorafenib (Nexavar,BAY43-9006)
12 Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma Completed NCT00467506 Phase 2 bispecific antibody and di-DTPA-131I
13 An Open Label, Two Stage, Phase II Study to Evaluate the Efficacy and Tolerability of ZD6474 in Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Carcinoma. Completed NCT00098345 Phase 2 ZD6474 (vandetanib)
14 Phase 2 Study of Anlotinib in Advanced Medullary Thyroid Carcinoma Completed NCT01874873 Phase 2 Anlotinib
15 An Open Label Multi-Center Phase II Study of RAD001 in Advanced Thyroid Cancer Completed NCT01164176 Phase 2 everolimus
16 A Phase II Study of ZD 1839 (IRESSA®) in Patients With Advanced Thyroid Cancer Completed NCT00095836 Phase 2 Gefitinib
17 A Multi-center , Opened, Phase II Study of Safety and Efficacy of Sulfatinib in Advanced Medullary Thyroid Carcinoma ( MTC) and Iodine-refractory Differentiated Thyroid Carcinoma (DTC) Completed NCT02614495 Phase 2 Surufatinib
18 Pharmacokinetic and Imaging Optimization Study of Pretargeted Immuno-PET Using the Anti-CEA x Anti-HSG TF2 Bispecific Antibody and 68Ga-IMP-288 Peptide in Patients With Recurrences of Medullary Thyroid Carcinoma. Completed NCT01730638 Phase 1, Phase 2 • TF2 and 68 Ga-IMP-288
19 Phase I/II Radioimmunotherapy With High-Dose 90Y-Labeled Humanized MN-14 Alone or Combined With Doxorubicin and Peripheral Blood Stem Cell Rescue (PBSCR) in Medullary Thyroid Cancer (MTC) Grant Application Title: Radioimmunotherapy of MTC With Y-90 Humanized MN14 Anti-CEA Mab and Doxorubicin Completed NCT00004048 Phase 1, Phase 2 doxorubicin hydrochloride
20 Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
21 A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer Completed NCT00121628 Phase 2 AMG 706
22 A Phase II Study Of Hepatic Arterial Infusion Of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) For Unresectable Primary And Metastatic Cancers Of The Liver Completed NCT00096083 Phase 2 isolated perfusion;melphalan
23 Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma Completed NCT00887107 Phase 2 Sorafenib (nexavar)
24 Phase 2 of Sunitinib (Sutent) in Patients With Locally Advanced or Metastatic Anaplastic, Differentiated or Medullar Thyroid Cancer Completed NCT00510640 Phase 2 Sunitinib
25 Vaccine Therapy With Tumor Specific Mutated Ras Peptides and IL-2 or GM-CSF for Adult Patients With Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
26 Phase II Study of Sunitinib in Iodine Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of Thyroid With Functional Imaging Correlation Completed NCT00519896 Phase 2 sunitinib malate
27 A Phase II Study of Single Agent Depsipeptide (FK228) in Radioiodine (RAI)-Refractory Metastatic Non-medullary (Papillary, Follicular, and Hurthle Cell Variants) Thyroid Carcinoma Completed NCT00098813 Phase 2 romidepsin
28 Mono Centre, Open Label Proof of Concept Study SOM230 in Progressive Medullary Thyroid Cancer Patients and the Combination With RAD001 Upon Progression Completed NCT01625520 Phase 2 SOM230 alone or in combination with RAD001.
29 Phase II Study of Capecitabine and Temozolomide for Progressive, Differentiated, Metastatic Neuroendocrine Cancers Completed NCT00869050 Phase 2 Capecitabine;Temozolomide
30 A Phase 2 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including Rearranged in Transfection (RET) Fusion-Positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation Recruiting NCT04280081 Phase 2 Selpercatinib
31 Phase II Study of Sorafenib (BAY 43-9006) in Patients With Metastatic Medullary Thyroid Carcinoma Active, not recruiting NCT00390325 Phase 2 Sorafenib;Sorafenib Tosylate
32 Phase I/II Trial of Vandetanib (ZD6474, ZACTIMA) in Children and Adolescents With Hereditary Medullary Thyroid Carcinoma Active, not recruiting NCT00514046 Phase 1, Phase 2 Vandetanib
33 A Phase II Study Exploring the Safety and Efficacy of Nintedanib (BIBF1120) as Second Line Therapy for Patients With Either Differentiated or Medullary Thyroid Cancer Progressing After First Line Therapy. Active, not recruiting NCT01788982 Phase 2 Nintedanib;Placebo
34 Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers Active, not recruiting NCT00381641 Phase 2 Sunitinib;Sunitinib Malate
35 A Phase II Study to Evaluate the Effects of 177Lu-DOTATATE in Patients With Unresectable and Progressive Rare Metastatic Endocrine Carcinomas: Medullary Thyroid Cancer, Parathyroid Carcinoma, Pituitary Carcinoma, and Malignant Pheochromocytoma/Paraganglioma Not yet recruiting NCT04106843 Phase 2 Lutetium Lu 177 Dotatate
36 A Phase I/II Study to Evaluate the Efficacy and Toxicity of Imatinib Mesylate in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma Terminated NCT00354523 Phase 1, Phase 2 Capecitabine (Xeloda);DTIC-Dome (Dacarbazine);Gleevec (Imatinib Mesylate)
37 A Targeted Ph I/II Trial of ZD6474 (Vandetanib; CAPRELSA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Ca (MTC) Terminated NCT00923247 Phase 1, Phase 2 Bortezomib;Vandetanib
38 Phase II Trial of Irinotecan for Treatment of Metastatic Medullary Thyroid Cancer Terminated NCT00100828 Phase 2 irinotecan hydrochloride
39 Clinical Trial of Sir-Spheres® in Patients With Symptomatic or Progressive Hepatic Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2 octreotide acetate
40 Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer. Terminated NCT00647140 Phase 2
41 Randomized Double-blind Placebo Controlled Phase II Study to Evaluate the Efficacy and Safety of Sorafenib Treatment in Patients With Advanced (Recurrent, Persistent and/or Metastasizing) Medullary Thyroid Carcinoma Withdrawn NCT01736878 Phase 2 Sorafenib
42 Phase I Trial of NGR-TNF Administered Every 3 Weeks as a 1 Hour Intravenous Infusion in Patients With Solid Tumor Completed NCT00098943 Phase 1
43 A Phase I Pharmacokinetic, Pharmacodynamic, and Clinical Study of the Combination of the Angiogenesis Inhibitor SU5416 and Paclitaxel in Recurrent or Metastatic Carcinoma of the Head and Neck Completed NCT00005647 Phase 1 paclitaxel;semaxanib
44 A Phase I Study of Active Immunotherapy With Carcinoembryonic Antigen RNA-Pulsed, Autologous Human Cultured Dendritic Cells in Patients With Metastatic Malignancies Expressing Carcinoembryonic Antigen Completed NCT00004604 Phase 1
45 A Phase I Study Of Active Immunotherapy With Autologous Dendritic Cells Infected With CEA-6D Expressing Fowlpox -Tricom In Patients With Advanced Or Metastatic Malignancies Expressing CEA Completed NCT00027534 Phase 1
46 Phase I Clinical Trial Using a Novel CCK-2/Gastrin Receptor-localizing Radiolabelled Peptide Probe for Personalized Diagnosis and Therapy of Patients With Progressive or Metastatic Medullary Thyroid Carcinoma Completed NCT03246659 Phase 1 111In-CP04;111In-CP04 with co-administration of gelofusine/gelaspan
47 A Phase I, Pharmacokinetic, and Biologic Correlative Study of R115777 (NSC 702818) and Herceptin in Patients With Advanced Cancer Completed NCT00005842 Phase 1 tipifarnib
48 B-Uptake In Different Tumours Using The Boron Compounds BSH And BPA Completed NCT00062348 Phase 1 boronophenylalanine-fructose complex;sodium borocaptate
49 177Lu-PP-F11N for Receptor Targeted Therapy and Imaging (Theranostics) of Metastatic Medullary Thyroid Cancer - a Pilot and a Phase I Study. Recruiting NCT02088645 Phase 1 177Lu-PP-F11N
50 A Phase I Study of [111In-DTPA-D-Phe]-Octreotide in Patients With Refractory Malignancies Expressing Somatostatin Receptors Terminated NCT00002947 Phase 1

Search NIH Clinical Center for Thyroid Gland Medullary Carcinoma

Cochrane evidence based reviews: thyroid cancer, medullary

Genetic Tests for Thyroid Gland Medullary Carcinoma

Anatomical Context for Thyroid Gland Medullary Carcinoma

MalaCards organs/tissues related to Thyroid Gland Medullary Carcinoma:

40
Thyroid, Testes, Lymph Node, Liver, Bone, Lung, Breast

Publications for Thyroid Gland Medullary Carcinoma

Articles related to Thyroid Gland Medullary Carcinoma:

(show top 50) (show all 3902)
# Title Authors PMID Year
1
Efficacy and safety of concomitant 177Lu-DOTATATE and low-dose capecitabine in advanced medullary thyroid carcinoma: a single-centre experience. 61
32371670 2020
2
Gastropharyngeal Anastomotic Leak in Medullary Thyroid Carcinoma Following Initiation of a Tyrosine Kinase Inhibitor: A Case Report of an Unusual Side Effect of Cabozantinib. 61
32037846 2020
3
Cabozantinib as an emerging treatment for sarcoma. 61
32541320 2020
4
History of the multiple endocrine neoplasia workshops and overview of MEN2019. 61
32508314 2020
5
Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges. 61
32495250 2020
6
Medullary Thyroid Carcinoma in Children. 61
32571506 2020
7
Pourfour du Petit syndrome after medullary thyroid carcinoma surgery. 61
32553744 2020
8
Case of medullary thyroid carcinoma with desmoid-type fibromatosis. 61
32249519 2020
9
The tissue expression pattern of CA 19.9 is associated with oncological features in medullary thyroid carcinoma. 61
32535684 2020
10
Bone Metastases in Medullary Thyroid Carcinoma: High Morbidity and Poor Prognosis Associated With Osteolytic Morphology. 61
32072159 2020
11
Image-guided excision with I125 seed in lymph node metastasis of medullary thyroid carcinoma. 61
31607381 2020
12
Paraganglioma-like medullary thyroid carcinoma: A case report and literature review. 61
32125784 2020
13
Ultrasonographic characteristics of medullary thyroid carcinoma according to nodule size: application of the Korean Thyroid Imaging Reporting and Data System and American Thyroid Association guidelines. 61
32493032 2020
14
Poorly differentiated thyroid carcinoma : An underdiagnosed entity. 61
31273418 2020
15
Insulinoma-associated protein 1 immunostaining for various types of neuroendocrine tumors on FNA smears. 61
32573984 2020
16
Cabozantinib as an emerging treatment for sarcoma. 61
32453033 2020
17
Endocrinology in the time of COVID-19: Management of neuroendocrine neoplasms (NENs). 61
32554825 2020
18
High-specific-activity iodine 131 metaiodobenzylguanidine for the treatment of metastatic pheochromocytoma or paraganglioma: a novel therapy for an orphan disease. 61
32250976 2020
19
Ectopic ACTH Production and Cushing's Syndrome in a Patient with Parotid Acinic Cell Carcinoma with High-Grade Transformation: Tumor Context and Clinical Implications. 61
31363907 2020
20
Primary hyperparathyroidism as first manifestation in multiple endocrine neoplasia type 2A: an international multicenter study. 61
32375120 2020
21
False-positive staining of thyroglobulin distinguished from mixed medullary and follicular thyroid carcinoma by duplex in situ hybridization. 61
32522910 2020
22
A novel Double <i>RET</i> E768D/L790F mutation associated with a MEN2B-like phenotype. 61
32546069 2020
23
Renal calcitonin amyloidosis in a patient with disseminated medullary thyroid carcinoma. 61
32425063 2020
24
Insulinoma-associated protein 1 (INSM-1) expression in medullary thyroid carcinoma FNA: a multi-institutional study. 61
32197966 2020
25
Polymorphisms Within the RET Proto-Oncogene and Risk of Sporadic Medullary Thyroid Carcinoma. 61
32228166 2020
26
Chinese siblings with hereditary medullary thyroid carcinoma caused by RET mutation: implications for RET oncogene detection. 61
32408902 2020
27
First proof of association between autoimmune polyglandular syndrome and multiple endocrine neoplasia in humans. 61
32475862 2020
28
Clinical and prognostic value of neutrophil-lymphocyte ratio for patients with thyroid cancer: A meta-analysis. 61
32443286 2020
29
ProGRP AS A NOVEL BIOMARKER FOR THE DIFFERENTIAL DIAGNOSIS OF MEDULLARY THYROID CARCINOMA IN PATIENTS WITH THYROID NODULES. 61
32045291 2020
30
Impact of multikinase inhibitor approval on survival and physician practice patterns in advanced or metastatic medullary thyroid carcinoma. 61
32487357 2020
31
Modulatory Role of Single Nucleotide Polymorphisms of Distinct Genetic Pathways on Clinical Behavior of Medullary Thyroid Carcinoma. 61
32458635 2020
32
A Proposed Grading Scheme for Medullary Thyroid Carcinoma Based on Proliferative Activity (Ki-67 and Mitotic Count) and Coagulative Necrosis. 61
32452872 2020
33
Comparison of 5 Different PET Radiopharmaceuticals for the Detection of Recurrent Medullary Thyroid Carcinoma: A Network Meta-analysis. 61
32049723 2020
34
The KWAK TI-RADS and 2015 ATA guidelines for medullary thyroid carcinoma: Combined with cell block-assisted ultrasound-guided thyroid fine-needle aspiration. 61
31665550 2020
35
Commentary on the study of Li J et al: The KWAK TI-RADS and 2015 ATA guidelines for medullary thyroid carcinoma, combined with cell block-assisted ultrasound-guided thyroid fine-needle aspiration. 61
32064667 2020
36
Thyroid carcinoma metastasizing to the submandibular gland: Sonographic findings. 61
32045024 2020
37
Early thyroidectomy in multiple endocrine neoplasia: a four decade experience. 61
32464600 2020
38
3D-printed Titanium Prosthetic Reconstruction of the C2 Vertebra: Techniques and Outcomes of Three Consecutive Cases. 61
31809469 2020
39
Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib. 61
31900481 2020
40
MEN2-related pheochromocytoma: current state of knowledge, specific characteristics in MEN2B, and perspectives. 61
32388798 2020
41
Controversies in the surgical management of sporadic medullary thyroid carcinoma. 61
32011397 2020
42
Medullary Thyroid Carcinoma Surveillance Study: a Case-Series Registry. 61
32316860 2020
43
Medullary thyroid carcinoma co-existent with Hashimoto's thyroiditis diagnosed by a comprehensive cytological approach. 61
31883317 2020
44
What Is the Extent of Neck Dissection in Medullary Thyroid Carcinoma? 61
32311764 2020
45
The prognostic value of lymph node ratio in Medullary thyroid carcinoma: A multi-center study. 61
32389525 2020
46
Update on the Treatment of Medullary Thyroid Carcinoma in Patients with Multiple Endocrine Neoplasia Type 2. 61
32299110 2020
47
Effect of Lenvatinib on a Patient with Medullary Thyroid Carcinoma Liver Metastasis Caused by Multiple Endocrine Neoplasia Type 2A. 61
32219805 2020
48
Revisiting the genotype-phenotype correlation in children with medullary thyroid carcinoma: A report from the GPOH-MET registry. 61
31925938 2020
49
Grading of medullary thyroid carcinoma on the basis of tumor necrosis and high mitotic rate is an independent predictor of poor outcome. 61
32313184 2020
50
Cholecystokinin 2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study. 61
31519804 2020

Variations for Thyroid Gland Medullary Carcinoma

Cosmic variations for Thyroid Gland Medullary Carcinoma:

9 (show top 50) (show all 298)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88289588 VHL thyroid,NS,carcinoma,medullary carcinoma c.233A>T p.N78I 3:10142080-10142080 24
2 COSM87900604 TP53 thyroid,NS,carcinoma,medullary carcinoma c.637C>T p.R213* 17:7674894-7674894 24
3 COSM89661857 SMARCA4 thyroid,NS,carcinoma,medullary carcinoma c.2120T>C p.I707T 19:11008020-11008020 24
4 COSM92347003 RET thyroid,NS,carcinoma,medullary carcinoma c.2753T>C p.M918T 10:43121968-43121968 24
5 COSM92354392 RET thyroid,NS,carcinoma,medullary carcinoma c.1902C>G p.C634W 10:43114502-43114502 24
6 COSM92351620 RET thyroid,NS,carcinoma,medullary carcinoma c.1888T>C p.C630R 10:43114488-43114488 24
7 COSM92349912 RET thyroid,NS,carcinoma,medullary carcinoma c.1901G>A p.C634Y 10:43114501-43114501 24
8 COSM92347669 RET thyroid,NS,carcinoma,medullary carcinoma c.1900T>A p.C634S 10:43114500-43114500 24
9 COSM92360468 RET thyroid,NS,carcinoma,medullary carcinoma c.2038G>A p.A680T 10:43114638-43114638 24
10 COSM92352088 RET thyroid,NS,carcinoma,medullary carcinoma c.1858T>C p.C620R 10:43113654-43113654 24
11 COSM92347226 RET thyroid,NS,carcinoma,medullary carcinoma c.1900T>C p.C634R 10:43114500-43114500 24
12 COSM92352166 RET thyroid,NS,carcinoma,medullary carcinoma c.2650G>A p.E884K 10:43120123-43120123 24
13 COSM92348232 RET thyroid,NS,carcinoma,medullary carcinoma c.1924G>A p.V642I 10:43114524-43114524 24
14 COSM92348203 RET thyroid,NS,carcinoma,medullary carcinoma c.1946C>T p.S649L 10:43114546-43114546 24
15 COSM92353521 RET thyroid,NS,carcinoma,medullary carcinoma c.2723G>A p.R908K 10:43120196-43120196 24
16 COSM92360348 RET thyroid,NS,carcinoma,medullary carcinoma c.2627C>T p.A876V 10:43120100-43120100 24
17 COSM92361758 RET thyroid,NS,carcinoma,medullary carcinoma c.2296C>T p.P766S 10:43118384-43118384 24
18 COSM92364859 RET thyroid,NS,carcinoma,medullary carcinoma c.1983C>T p.H661= 10:43114583-43114583 24
19 COSM92348533 RET thyroid,NS,carcinoma,medullary carcinoma c.2752A>C p.M918L 10:43121967-43121967 24
20 COSM92366466 RET thyroid,NS,carcinoma,medullary carcinoma c.2680G>A p.G894S 10:43120153-43120153 24
21 COSM92364868 RET thyroid,NS,carcinoma,medullary carcinoma c.2733T>G p.G911= 10:43121948-43121948 24
22 COSM92360413 RET thyroid,NS,carcinoma,medullary carcinoma c.1852T>C p.C618R 10:43113648-43113648 24
23 COSM92347631 RET thyroid,NS,carcinoma,medullary carcinoma c.2761G>A p.E921K 10:43121976-43121976 24
24 COSM92371499 RET thyroid,NS,carcinoma,medullary carcinoma c.2756C>T p.A919V 10:43121971-43121971 24
25 COSM92355531 RET thyroid,NS,carcinoma,medullary carcinoma c.2304G>C p.E768D 10:43118392-43118392 24
26 COSM92369676 RET thyroid,NS,carcinoma,medullary carcinoma c.1859G>C p.C620S 10:43113655-43113655 24
27 COSM92355833 RET thyroid,NS,carcinoma,medullary carcinoma c.2701G>A p.E901K 10:43120174-43120174 24
28 COSM92362032 RET thyroid,NS,carcinoma,medullary carcinoma c.1902C>T p.C634= 10:43114502-43114502 24
29 COSM92351674 RET thyroid,NS,carcinoma,medullary carcinoma c.2206G>A p.G736R 10:43116653-43116653 24
30 COSM92347663 RET thyroid,NS,carcinoma,medullary carcinoma c.1886T>A p.L629Q 10:43114486-43114486 24
31 COSM92348595 RET thyroid,NS,carcinoma,medullary carcinoma c.2647G>T p.A883S 10:43120120-43120120 24
32 COSM92371517 RET thyroid,NS,carcinoma,medullary carcinoma c.1892A>G p.D631G 10:43114492-43114492 24
33 COSM92361920 RET thyroid,NS,carcinoma,medullary carcinoma c.1888T>G p.C630G 10:43114488-43114488 24
34 COSM92350213 RET thyroid,NS,carcinoma,medullary carcinoma c.1858T>A p.C620S 10:43113654-43113654 24
35 COSM92363615 RET thyroid,NS,carcinoma,medullary carcinoma c.1853G>A p.C618Y 10:43113649-43113649 24
36 COSM92357762 RET thyroid,NS,carcinoma,medullary carcinoma c.2137G>A p.E713K 10:43116584-43116584 24
37 COSM92356468 RET thyroid,NS,carcinoma,medullary carcinoma c.2771T>C p.F924S 10:43121986-43121986 24
38 COSM92368621 RET thyroid,NS,carcinoma,medullary carcinoma c.2249C>G p.A750G 10:43116696-43116696 24
39 COSM92360106 RET thyroid,NS,carcinoma,medullary carcinoma c.1804A>G p.I602V 10:43113600-43113600 24
40 COSM92356863 RET thyroid,NS,carcinoma,medullary carcinoma c.2117T>C p.V706A 10:43114717-43114717 24
41 COSM92371161 RET thyroid,NS,carcinoma,medullary carcinoma c.2242G>T p.G748C 10:43116689-43116689 24
42 COSM92354502 RET thyroid,NS,carcinoma,medullary carcinoma c.2180G>A p.G727E 10:43116627-43116627 24
43 COSM92355240 RET thyroid,NS,carcinoma,medullary carcinoma c.2256C>T p.Y752= 10:43116703-43116703 24
44 COSM92351910 RET thyroid,NS,carcinoma,medullary carcinoma c.2041C>T p.Q681* 10:43114641-43114641 24
45 COSM92347619 RET thyroid,NS,carcinoma,medullary carcinoma c.2732G>A p.G911D 10:43121947-43121947 24
46 COSM92352077 RET thyroid,NS,carcinoma,medullary carcinoma c.1843G>A p.E615K 10:43113639-43113639 24
47 COSM97107822 NRAS thyroid,NS,carcinoma,medullary carcinoma c.182A>T p.Q61L 1:114713908-114713908 24
48 COSM97107359 NRAS thyroid,NS,carcinoma,medullary carcinoma c.182A>G p.Q61R 1:114713908-114713908 24
49 COSM87161590 MGA thyroid,NS,carcinoma,medullary carcinoma c.1228G>T p.E410* 15:41696238-41696238 24
50 COSM97714722 MDC1 thyroid,NS,carcinoma,medullary carcinoma c.6266C>A p.T2089N 6:30700469-30700469 24

Expression for Thyroid Gland Medullary Carcinoma

Search GEO for disease gene expression data for Thyroid Gland Medullary Carcinoma.

Pathways for Thyroid Gland Medullary Carcinoma

GO Terms for Thyroid Gland Medullary Carcinoma

Cellular components related to Thyroid Gland Medullary Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.56 SSTR5 SSTR4 SSTR3 SSTR2 SSTR1 RET
2 neuron projection GO:0043005 9.1 SSTR5 SSTR4 SSTR3 SSTR2 SSTR1 CALCA

Biological processes related to Thyroid Gland Medullary Carcinoma according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.19 TG SSTR5 SSTR4 SSTR3 SSTR2 SSTR1
2 G protein-coupled receptor signaling pathway GO:0007186 10.03 SSTR5 SSTR4 SSTR3 SSTR2 SSTR1 SST
3 gene silencing by miRNA GO:0035195 9.97 MIR9-1 MIR31 MIR222 MIR187 MIR183 MIR138-1
4 negative regulation of inflammatory response GO:0050728 9.78 MIR31 MIR222 MIR187 MIR138-1
5 cerebellum development GO:0021549 9.72 SSTR3 SSTR2 SSTR1
6 negative regulation of osteoblast differentiation GO:0045668 9.71 MIR9-1 MIR138-1 MEN1
7 miRNA mediated inhibition of translation GO:0035278 9.71 MIR9-1 MIR31 MIR222 MIR138-1
8 response to starvation GO:0042594 9.69 SSTR3 SSTR2 SSTR1
9 forebrain development GO:0030900 9.67 SSTR4 SSTR3 SSTR2 SSTR1
10 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.65 SSTR5 SSTR4 SSTR3 SSTR2 SSTR1
11 negative regulation of cell proliferation GO:0008285 9.65 SSTR5 SSTR4 SSTR3 SSTR2 SSTR1 SST
12 cellular response to estradiol stimulus GO:0071392 9.63 SSTR3 SSTR2 SSTR1
13 neuropeptide signaling pathway GO:0007218 9.63 SSTR5 SSTR4 SSTR3 SSTR2 SSTR1 CALCA
14 cellular response to glucocorticoid stimulus GO:0071385 9.62 SSTR5 SSTR4 SSTR3 SSTR2
15 detection of temperature stimulus involved in sensory perception of pain GO:0050965 9.58 NTRK1 CALCA
16 negative regulation of osteoblast proliferation GO:0033689 9.57 MIR9-1 MIR138-1
17 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.56 MIR31 MIR222
18 hormone-mediated apoptotic signaling pathway GO:0008628 9.52 SSTR3 SST
19 somatostatin signaling pathway GO:0038170 9.02 SSTR5 SSTR4 SSTR3 SSTR2 SSTR1

Molecular functions related to Thyroid Gland Medullary Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.8 SSTR5 SSTR4 SSTR3 SSTR2 SSTR1 CCKBR
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.73 MIR9-1 MIR31 MIR222 MIR187 MIR183 MIR138-1
3 peptide binding GO:0042277 9.55 SSTR5 SSTR4 SSTR3 SSTR2 SSTR1
4 neuropeptide binding GO:0042923 9.35 SSTR5 SSTR4 SSTR3 SSTR2 SSTR1
5 somatostatin receptor activity GO:0004994 9.02 SSTR5 SSTR4 SSTR3 SSTR2 SSTR1

Sources for Thyroid Gland Medullary Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....